These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36396461)

  • 21. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
    Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.
    Xiao D; Ling KHJ; Tarnowski T; Majeed SR; German P; Kearney BP; Zhao Y; Chen YS; Ma L; Zhang T
    Anal Biochem; 2020 Mar; 593():113611. PubMed ID: 32035040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV.
    Coyle RP; Morrow M; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL; Castillo-Mancilla JR
    J Antimicrob Chemother; 2020 Jun; 75(6):1591-1598. PubMed ID: 32211787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
    Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
    Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
    Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
    Lanier ER; Ptak RG; Lampert BM; Keilholz L; Hartman T; Buckheit RW; Mankowski MK; Osterling MC; Almond MR; Painter GR
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2901-9. PubMed ID: 20439609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
    Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
    Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
    Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
    Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
    J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring.
    Niu X; Kubiak RW; Siriprakaisil O; Klinbuyaem V; Sukrakanchana PO; Cressey R; Okochi H; Gandhi M; Cressey TR; Drain PK
    Open Forum Infect Dis; 2022 Aug; 9(8):ofac405. PubMed ID: 36004315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
    Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
    Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
    Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
    Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
    Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
    Castillo-Mancilla JR; Morrow M; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL
    Clin Infect Dis; 2019 Apr; 68(8):1335-1342. PubMed ID: 30137238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.
    Castillo-Mancilla JR; Searls K; Caraway P; Zheng JH; Gardner EM; Predhomme J; Bushman LR; Anderson PL; Meditz AL
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):428-32. PubMed ID: 25328112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
    Margot NA; Liu Y; Miller MD; Callebaut C
    Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.
    Feng JY; Ly JK; Myrick F; Goodman D; White KL; Svarovskaia ES; Borroto-Esoda K; Miller MD
    Retrovirology; 2009 May; 6():44. PubMed ID: 19439089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy.
    Coyle RP; Schneck CD; Morrow M; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL; Castillo-Mancilla JR
    AIDS Behav; 2019 Dec; 23(12):3493-3502. PubMed ID: 30798457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).
    Hirt D; Ekouévi DK; Pruvost A; Urien S; Arrivé E; Blanche S; Avit D; Amani-Bosse C; Nyati M; Legote S; Ek ML; Say L; McIntyre J; Dabis F; Tréluyer JM
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2961-7. PubMed ID: 21464249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.